癌症診斷領域的合作與許可協議（2018-2026 年）

Cancer Diagnostic Collaboration and Licensing Deals 2018-2026

出版日期: 2026年05月01日 | 出版商:

Current Partnering | 英文 450+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

癌症診斷領域併購的決定性指標

癌症診斷領域的合作處於精準醫療和腫瘤學的交會點，其交易結構反映了診斷技術、數據和治療方法開發策略的整合。

本報告對癌症診斷領域的 800 多項合作與許可協議進行了全面系統的分析，清楚地展示了整個市場夥伴關係的設計、談判和執行方式，並以證據為基礎進行了闡述。

清楚了解市場標準

本報告將使您能夠準確了解癌症診斷相關交易的實際結構，從而使您能夠：

自信地對標類似交易
對相關交易中的預付款、里程碑付款和特許權使用費結構進行詳細分析。
設定切合實際的市場參數
您可以清楚地了解合約條款如何因技術類型、應用和合作夥伴情況而異。
支持基於證據的評估和合約結構確定。
內部討論應基於實際交易數據，而非假設。
了解大型公司如何處理交易
在精準主導和技術主導的環境下，可視化合作夥伴行為和迭代交易結構。
全面了解交易結構和執行情況
本報告提供關鍵交易資料以及相關合約文件，使您能夠詳細了解實際合約的構成方式。

這包括：

授予和保留的權利
負責開發和商業化
財務結構和支付觸發機制
關鍵合約條款和保障措施
這種程度的透明度在癌症診斷夥伴關係中至關重要，尤其是在伴隨診斷、數據整合和共同開發治療方法是關鍵考慮因素的情況下，以便了解價值、風險和控制是如何分配的。
專為實際業務發展和策略制定而設計。

本報告廣泛用於以下用途：

在診斷和腫瘤學領域建立夥伴關係和標竿學習
在清晰的市場環境下準備談判
評估技術合作夥伴和合作機會
支持以可靠證據為基礎的數據驅動型內部策略。
本報告內容
在癌症診斷領域達成了 800 多項合作與許可協議。
財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
一個可全文搜尋的合約目錄（依公司、技術和應用程式分類）。
可直接查閱向美國證券交易委員會提交的合約和原始文件。
交易趨勢分析、關鍵交易和活躍負責人
關於癌症診斷領域交易的可靠、基於證據的參考資料。
本報告結合全面的交易報告和合約層面的深入分析，為如何在癌症診斷領域建立、談判和評估夥伴關係提供了可靠的、基於證據的指導。

交易清單
交易清單 - 癌症診斷相關交易（亞利桑那州）（按公司）
交易清單 - 癌症診斷相關交易（按交易類型分類）
交易清單 - 癌症診斷相關交易（依治療領域分類）
交易類型的定義
關於這家研究公司
當前夥伴關係
目前合約
理想合作夥伴最新報告的標題

簡介目錄

Product Code: CP22013

The definitive benchmark for cancer diagnostics dealmaking

Cancer diagnostics partnering sits at the intersection of precision medicine and oncology, with deal structures reflecting the integration of diagnostic technologies, data, and therapeutic development strategies.

This report provides a comprehensive and structured analysis of 800+ cancer diagnostic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how cancer diagnostic deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by technology type, application, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a precision medicine-driven and technology-led landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within cancer diagnostic partnerships, particularly where companion diagnostics, data integration, and co-development with therapeutics are key considerations.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark diagnostic and oncology partnerships
Prepare for negotiations with well-defined market context
Evaluate technology partners and collaboration opportunities
Support internal strategy with robust, defensible data
What's included
800+ cancer diagnostic collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, technology, and application)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for cancer diagnostics dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how cancer diagnostic partnerships are structured, negotiated, and valued.

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer diagnostic dealmaking

2.1. Introduction
2.2. Cancer diagnostic deals over the years
2.3. Most active cancer diagnostic dealmakers
2.4. Cancer diagnostic deals by deal type
2.5. Cancer diagnostic deals by therapy area
2.6. Cancer diagnostic deals by industry sector
2.7. Deal terms for cancer diagnostic deals
- 2.7.1 Cancer diagnostic deals headline values
- 2.7.2 Cancer diagnostic deal upfront payments
- 2.7.3 Cancer diagnostic deal milestone payments
- 2.7.4 Cancer diagnostic royalty rates